Ligand Pharmaceuticals (LGND) Change in Acquisitions & Divestments (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $119.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 210.69% year-over-year to $119.4 million; the trailing twelve-month figure through Mar 2026 stood at $240.5 million (up 2163.5% YoY), and the FY2025 full-year result was $159.6 million, up 381.68% from the prior year.
• Change in Acquisitions & Divestments eased to $119.4 million in Q1 2026, from $121.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $184.7 million in Q4 2022 to a low of -$152.7 million in Q3 2022.
• A 5-year average of $33.4 million and a median of $38.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 229.58% in 2022 and soared 2148.79% in 2025, its largest moves.
• Tracing LGND's Change in Acquisitions & Divestments over 5 years: stood at $184.7 million in 2022, then sank by 127.56% to -$50.9 million in 2023, then jumped by 110.57% to $5.4 million in 2024, then soared by 2148.79% to $121.0 million in 2025, then retreated by 1.35% to $119.4 million in 2026.
• Business Quant data shows LGND's Change in Acquisitions & Divestments at $119.4 million in Q1 2026, $121.0 million in Q4 2025, and -$44.6 million in Q3 2025.